SLC5A2 and diabetic kidney disease: Current therapy for DKD is limited to strict glycemic control and blood pressure control with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors (3).